Dogwood Therapeutics Increases Authorized Shares and Re-elects Board at 2026 Annual Meeting

Dogwood Therapeutics, Inc. (formerly Virios Therapeutics) reported the results of its Annual Meeting of Stockholders held on June 16, 2026. Stockholders approved an amendment to the Certificate of Incorporation to increase the authorized share capital to 200,000,000 total shares, consisting of 195,000,000 shares of common stock and 5,000,000 shares of preferred stock. The amendment became effective upon filing with the Secretary of State of Delaware on June 17, 2026. Additionally, seven directors were re-elected to the board: Abel De La Rosa, Greg Duncan, David Keefer, John C. Thomas, Jr., Melvin Toh, Richard J. Whitley, and Alan Yu. Stockholders ratified the appointment of Forvis Mazars, LLP as the independent accounting firm for 2026 and approved executive compensation. Following an advisory vote on the frequency of future executive compensation votes, the Board determined that these votes will occur annually. The meeting saw high participation, with 95.17% of the voting power represented.